Future studies investigating the nature of CD8+ T cell subsets in responses to combinatorial focal therapy and immunotherapy are warranted, including identifying treatment conditions and interventions that can further influence tumor antigen-specific CD8+ T cell programming and tissue trafficking properties. Here, CD8A is linked to neoplasm.